ClinicalTrials.gg
Active, not recruitingNCT02690441PEXACOGUpdated Apr 28, 2026

Physical Exercise Augmented CBT for GAD

An interventional study of Cognitive Behavioural Therapy and Physical Exercise in Generalized Anxiety Disorder, sponsored by Solli Distriktspsykiatriske Senter. Active, not recruiting at 1 site in Norway. Open to participants aged 60 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Solli Distriktspsykiatriske Senter · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
60 Years to 75 Years
Sex
All
01

Study summary

Generalised anxiety disorder (GAD) is a severe and debilitating anxiety disorder that is highly prevalent among older adults. Anxiety and GAD is a well-documented risk factor for the development of other severe conditions such as depression and dementia, and effective treatments are called for. However, recommended treatment for GAD has consistently been found to yield blunted response rates for older adults compared to younger patients.

The purpose of this study is to evaluate the effects of exercise-augmented cognitive behaviour therapy for older adults with GAD. Exercise augmented CBT is expected to yield better results than standard CBT in terms of greater reduction of symptoms and increased rates of remission. The investigators will also investigate the effects of treatment on biological, physiological and neuropsychological measures.

02

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • GAD
  • CBT
  • Physical exercise
  • Older adults
03

In context

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

This study's enrollment of 53 is below the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.

Browse Generalized Anxiety Disorder studies →

Lead sponsor

Solli Distriktspsykiatriske Senter is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary diagnosis of GAD

Exclusion criteria

Exclusion Criteria:

  • Substance abuse
  • Use of benzodiazepines, use of antipsychotica
  • Lack of ability to stabilize other psychotropic medication during participating in the study
  • Medical condition that precludes participation in physical exercise
  • Severe major depression as determined by the MINI International Neuropsychiatric Interview
  • Life-time history of psychosis and/or mania
  • Participation in other ongoing psychotherapy
  • Organic brain disease
  • Positive screening for dementia with
  • Currently engaged in a regular physical exercise program
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    CBT augmented with physical exercise

    Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of physical exercise pre-treatment, and 10 weeks of physical exercise alongside CBT. Both treatment and physical exercise is administered individually.

    Behavioral: Cognitive Behavioural Therapy · Behavioral: Physical Exercise

  • Active comparator
    CBT and placebo control

    Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of placebo control (15 minutes telephone follow-up call each week) pre-treatment, and 10 weeks of attention placebo alongside CBT. Both treatment and placebo control is administered individually.

    Behavioral: Cognitive Behavioural Therapy · Behavioral: Placebo control

Interventions

  • BehavioralCognitive Behavioural Therapy

    Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.

  • BehavioralPhysical Exercise

    Manualised exercise. 15 weekly sessions with instructor, and two weekly unsupervised sessions performed individually.

  • BehavioralPlacebo control

    One follow-up telephone call à 15 minutes each week for 15 weeks. Aims to control for therapist contact in physical exercise condition and total duration of treatment.

    Also known as: Telephone follow-up

06

What researchers measure

Primary outcomes

  1. Changes in The Penn State Worry Questionnaire

    Assesses symptom severity of GAD

    Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up

  2. Change in clinical diagnosis after treatment assessed by independent, blinded rater with Anxiety Disorders Interview Schedule (ADIS-IV)

    Remission rates. Assessed by independent, blinded rater with Anxiety Disorders Interview Schedule (ADIS-IV)

    Time frame: Baseline and post-treatment (up to 20 weeks after baseline)

Secondary outcomes

  1. Geriatric Anxiety Inventory

    Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up

  2. Generalized Anxiety Disorder 7-item scale (GAD-7)

    Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up

  3. Beck Anxiety Inventory

    Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up

  4. Beck Depression Inventory - II

    Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up

  5. Bergen Insomnia Scale

    Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up

  6. Quality of Life Inventory

    Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up

  7. International Physical Activity Questionnaire (IPAQ)

    Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up

  8. 5-item Treatment Credibility and Expectancy Scale (CES)

    Time frame: Baseline

Other outcomes

  1. Function and structure of prefrontal lobes and limbic system

    Functional Magnetic Resonance Imaging (fMRI) conducted with a 3-Tesla scanner.

    Time frame: Baseline, post-treatment (up to 20 weeks after baseline) and 12 months follow-up

  2. Blood samples

    Serum concentrations of mature and pro brain-derived neurotropic factor

    Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up

  3. Saliva samples

    To measure cortisol

    Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up

  4. Three subtests from Delis-Kaplan Executive Function System battery (D-KEFS; Delis, Kaplan & Kramer, 2001)

    Measures executive function

    Time frame: Baseline, post-treatment (up to 20 weeks after baseline) and 12 months follow-up

  5. Wisconsin Card Sorting Test: Computer Version 4 research edition (WCST-CV4; Heaton, PAR staff & Goldin 2003).

    Measures executive function

    Time frame: Baseline, post-treatment (up to 20 weeks after baseline) and 12 months follow-up

  6. The California Verbal Learning Test (CVLT; Delis, Kramer & Kaplan, 1994).

    Measures memory

    Time frame: Baseline, post-treatment (up to 20 weeks after baseline) and 12 months follow-up

  7. Wechsler Abbreviated Scale of Intelligence

    Two subtests from Wechsler Abbreviated Scale of Intelligence (WASI; Wechsler, 1999) will be administered to assess IQ level.

    Time frame: Baseline

  8. Ambulatory Electrocardiogram (ECG)

    Measures heart rate variability (HRV)

    Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up

  9. Ekblom-Bak submaximal ergometer cycle test

    Test for prediction of VO2 max, which gives an indication of physical fitness

    Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up

  10. Strength test battery

    Measures submaximal physical strength, which gives an indication of physical fitness.

    Time frame: Baseline, after pre-treatment (up to 8 weeks after baseline), post-treatment (up to 20 weeks after baseline), 6 months follow-up and 12 months follow-up

07

Study locations

1 site
08

References and documents

Publications

  • Sirevag K, Stavestrand SH, Sjobo T, Endal TB, Nordahl HM, Andersson E, Nordhus IH, Rekdal A, Specht K, Hammar A, Halmoy A, Mohlman J, Hjelmervik H, Thayer JF, Hovland A. Physical exercise augmented cognitive behaviour therapy for older adults with generalised anxiety disorder (PEXACOG): a feasibility study for a randomized controlled trial. Biopsychosoc Med. 2023 Jul 19;17(1):25. doi: 10.1186/s13030-023-00280-7. PubMed 37468978 ↗
  • Stavestrand SH, Sirevag K, Nordhus IH, Sjobo T, Endal TB, Nordahl HM, Specht K, Hammar A, Halmoy A, Martinsen EW, Andersson E, Hjelmervik H, Mohlman J, Thayer JF, Hovland A. Physical exercise augmented cognitive behaviour therapy for older adults with generalised anxiety disorder (PEXACOG): study protocol for a randomized controlled trial. Trials. 2019 Mar 18;20(1):174. doi: 10.1186/s13063-019-3268-9. PubMed 30885256 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Oct 2023, 91 months.

Of 176 non-industry interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's 91 months is above that.

Counting every sponsor, half of 185 studies reached it within 28 months; a quarter within 15 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2016
First posted
Feb 24, 2016
StartActual
Mar 2016
Primary completionActual
Oct 2023
CompletionEst.
Dec 2026
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02690441
Lead sponsor
Solli Distriktspsykiatriske Senter
Responsible party
Sponsor
First posted
Feb 24, 2016
Start date
Mar 2016
Primary completion
Oct 2023
Completion
Dec 2026 (estimated)
Last update
Apr 28, 2026

Study contacts

Anders Hovland, PhD
principal investigator · Solli DPS, University of Bergen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion